Assyro AI

FDA Orange Book · active-ingredient family

Ursodiol

Ursodiol is approved as 2 brand and 22 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:URSO 250 · NDA 020675

2

Brand (NDA)

22

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, tablet

ProductApplicantApplicationTEApproved
URSO 250RLD×2ABBVIENDA 020675Dec 10, 1997
ACTIGALLRLD×2TEVA BRANDED PHARMNDA 019594ABDec 31, 1987

Generic (ANDA) products (22)

ProductApplicantApplicationTEApproved
URSODIOL×2STRIDES PHARMAANDA 210344Jan 16, 2026
URSODIOL×2EPIC PHARMA LLCANDA 214717ABAug 14, 2024
URSODIOLAUROBINDO PHARMA LTDANDA 214849ABNov 28, 2022
URSODIOLRK PHARMAANDA 214329ABJul 28, 2021
URSODIOLZYDUS LIFESCIENCESANDA 214295ABOct 16, 2020
URSODIOL×2STRIDES PHARMAANDA 213504ABAug 20, 2020
URSODIOLCHARTWELL RXANDA 213555ABAug 17, 2020
URSODIOL×2LGM PHARMAANDA 205789May 08, 2020
URSODIOLRISINGANDA 213200ABFeb 12, 2020
URSODIOLHIBROW HLTHCAREANDA 212452ABOct 30, 2019
URSODIOL×2ZYDUS LIFESCIENCESANDA 211145ABOct 30, 2018
URSODIOLAMNEAL PHARMS COANDA 211301Oct 16, 2018
URSODIOLABHAI LLCANDA 210707ABMay 17, 2018
URSODIOL×2PH HEALTHANDA 202540ABFeb 14, 2013
URSODIOL×2IMPAX LABS INCANDA 200826Dec 23, 2011
URSODIOL×2GLENMARK PHARMS LTDANDA 090801ABJul 12, 2011
URSODIOLQUAGENANDA 090530Feb 17, 2010
URSODIOL×2TEVA PHARMS USAANDA 079184May 13, 2009
URSODIOLLANNETT CO INCANDA 079082ABDec 15, 2008
URSODIOLIMPAX LABS INCANDA 077895Jul 27, 2006
URSODIOLTEVA PHARMSANDA 075592May 25, 2000
URSODIOLEPIC PHARMAANDA 075517ABMar 14, 2000

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Ursodiol — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.